Re&Up Products Achieve C2C Certified Circularity
Re&Up is setting new standards in circularity.
The textile-to-textile recycler has become the first company in the textile industry to be C2C Certified Circularity for all products by the Cradle to Cradle Products Innovation Institute.
More from Sourcing Journal
EU's Textile Recycling Excellence Project Creates New Blueprint
Chemical Textile Recycler Eeden Closes $20M Funding Round
Sci-Lume Labs Takes Home $30K for Crystal Clear Circularity
The Sanko Group venture announced that its Next-Gen Recycled Cotton (Pre-Consumer) and Next-Gen Recycled Cotton (Post-Consumer) achieved C2C Certified Circularity at Platinum level. The company's textile-to-textile recycled polyester chips was awarded C2C Certified Circularity at Silver level.
These levels recognize recycled content and Re&Up's full-system approach to circularity—from sourcing and traceability to infrastructure compatibility and reuse pathways.
Ebru Özküçük Guler, Re&Up's chief sustainability offer, said the certifications reflect the 'robust technology of our approach and our commitment to creating solutions that don't compromise on quality, scale, or impact.'
Cradle to Cradle Products Innovation Institute introduced C2C Certified Circularity in 2024. The tool evaluates whether a product is intentionally designed for continuous, safe, and high-value reuse. This assessment is conducted by Eco Intelligent Growth, an accredited third-party assessor. The assessment looks at the percentage of compatible materials for recycling, end-of-life recovery systems, publicly available circularity data and cycling instructions, effective integration of recycled content and chemical safety.
To achieve Platinum level, the product must meet several criteria, including the identification of at least two intended cycling pathways for both the product and its materials. Additionally, the percentage of recycled and/or renewable content—measured by weight—must reach the highest level that is technically feasible.
To achieve Silver level, partnerships for the recovery and processing of the product must be in place. Furthermore, the percentage of recycled and/or renewable content—by weight—must meet or exceed industry averages or align with established best practices.
'The Product Circularity category is designed to separate ambitious claims from proven impact,' said Nienke Steen, director of apparel, textiles and footwear at the Cradle to Cradle Products Innovation Institute. 'Re&Up has demonstrated that its fiber production is not just compatible with circularity, it's purpose-built for it.'
In March, Re&Up and Puma signed a letter of intent to scale to scale textile-to-textile recycling and reduce reliance on virgin materials across the athletic giant's supply chain. Since launching in 2023, Re&Up has been used throughout Isko's denim collections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 days ago
- Yahoo
Florida AG Announces 44 Arrests in Retail Crime Blitz
Florida Attorney General James Uthmeier announced late last week that officials throughout the state arrested 44 people on retail crime charges and recovered $207,000 worth of merchandise. The state participated in a nationwide blitz on retail crime, the attorney general said. Police said those arrested stole 'a range of merchandise, including personal grooming products, clothing, sporting goods and home repair tools.' More from Sourcing Journal Majority of Americans Believe Tariffs Threaten Their Finances Exclusive: Over One-Third of Retail Execs Say They Will Adjust Pricing In the Face of Tariffs Majority of Consumers Say They Will Decrease Spending Once Tariffs Kick In Uthmeier said his office collaborated with the Florida Department of Law Enforcement and the Florida Organized Retail Crime Exchange (FORCE) on the crackdown, and noted that he was pleased with the results of the partnership. 'Due to great coordination among our state law enforcement and Florida Organized Retail Crime Exchange, 44 criminals were arrested as part of a nationwide organized retail theft blitz,' Uthmeier said in a statement. 'The rule of law means something in Florida; this is another example of our state working with law enforcement to stop criminals.' FDLE Commissioner Mark Glass said the blitz further evidences Florida's status as 'a law-and-order state,' a reputation the Sunshine State has taken measures to uphold relative to retail crime. Last year, Florida Governor Ron DeSantis signed a law tightening the penalties for retail crime in the state, after criticizing blue states like California and New York for leniency on theft. According to Capital One Shopping data, Florida retailers lost more than $5.4 billion in revenue to theft in 2022, and retail theft per capita in the state is 12.2 percent lower than the nationwide average. That same data set shows that the instances of retail theft per capita in New York and California are 18.4 percent and 17 percent lower than the national average, respectively. The law stipulates that anyone who participates in a retail crime operation inclusive of five or more people can be charged with a third-degree felony, with a punishment of up to five years in prison and added harsher punishment for those who perpetuate organized crime rings via social media. Perhaps most significantly, the law also enables officials to charge anyone who has committed multiple instances of retail theft in Florida within a 120-day window with a felony; prior to DeSantis signing the law, only repeat offenders inside a 30-day window could be charged with a felony. Uthmeier's office did not provide details about the number of felonies the arrested retail crime suspects have been charged with, nor did the attorney general disclose the retailers that were impacted by the alleged thieves' operations. R. Scott Shalley, president of the Florida Retail Federation, said the work the trade organization has done with various state agencies has helped curtail the effect of crime on retailers' bottom lines in the state. 'Florida's retailers deeply value our strong partnership with law enforcement—our most important ally in the fight against organized retail crime,' Shalley said in a statement. 'The success of this nationwide blitz, and Florida's significant role in it, underscores the impact of collaboration through FORCE. We commend Attorney General Uthmeier, FDLE, and all participating agencies for their continued commitment to safeguarding Florida's businesses, employees, and customers from these criminal networks.'
Yahoo
2 days ago
- Yahoo
Majority of Americans Believe Tariffs Threaten Their Finances
The vast majority of Americans believe President Donald Trump's tariff regime poses an acute threat to their personal finances, and more than half believe the United States economy is veering into dangerous territory. A May survey of more than 1,000 U.S. shoppers revealed that 56 percent think that amid lingering inflation and macroeconomic and geopolitical turmoil, the country's economy is headed in the wrong direction. Bankrate's Consumer Sentiment Survey showed that nearly two in three consumers (65 percent) expect the duties on foreign-made products to have negative personal financial impacts. More from Sourcing Journal US Companies Take Trump Tariff Suit to Supreme Court Florida AG Announces 44 Arrests in Retail Crime Blitz Exclusive: Over One-Third of Retail Execs Say They Will Adjust Pricing In the Face of Tariffs While inflation has been softening and Trump is pushing to solidify his first-term tax cuts before they expire at the end of 2025, shoppers are finding their personal experiences incongruous with the relief that's been promised. In fact, 97 percent of survey takers said they had clocked higher prices over the past year on at least one area of spending, including groceries (91 percent), consumer products (52 percent), travel (40 percent) and personal care services (39 percent). Tariffs are '[o]vershadowing any bright spots in the U.S. economy,' as economists point to the possibility that duties could usher in more inflation and even a recession. The administration's current trade strategy, which centers on taxing imports from across the globe, is far more aggressive than the punitive duties Trump levied against China during his first term in office. In fact, tariffs incurred on global apparel imports this April reached their highest levels in decades. 'While tariffs are one of the president's favorite policy tools, most Americans see higher taxes on imported goods as being a losing proposition for their personal finances,' wrote Bankrate senior economic analyst Mark Hamrick. 'This, after they had previously identified inflation as the top economic issue of the 2024 presidential campaign.' The consumer financial services company broke down responses by political party, and found that all shoppers surveyed were likely to say that tariff-centric trade policy would worsen their economic standing. Perhaps not surprisingly, 91 percent of Democrats took that stance, though 62 percent of independents and 46 percent of Republicans said the same. Some 36 percent of Republicans said the opposite—that new duties could help pad their pocketbooks—along with just 13 percent of independents and 5 percent of Democrats. Political ideologies play a big role in Americans' perceptions of the country's economy, Bankrate found. Even though tariffs are unpopular across the board, only Republican survey respondents were more likely to believe that the economy is on a favorable trajectory, at 58 percent. Meanwhile, just 17 percent of independents and 7 percent of Democrats said the same. An overwhelming majority of Democrats (83 percent) said they believe the economy is taking an ominous turn, along with 58 percent of Independents. More than one-quarter (27 percent) of Republicans agreed, too. Bankrate's analysis noted that this breakdown is not entirely surprising; in October, before Trump was elected, 83 percent of Republicans believed the economy was on the wrong track, while 62 percent of independents and just 27 percent of Democrats agreed. That's because many consumers tend to have a more optimistic view of the economy when their party is the one in charge. Political affiliations have definite correlations with attitudes about the economy, so too do age and income, Bankrate's research showed. Younger shoppers—Gen Z and millennials, at 65 percent and 69 percent, respectively— believe that the Trump tariffs will be hard on their wallets. And notably, 68 percent of baby boomers are in alignment. Gen Xers were the most optimistic, with one-quarter of 45-to-60-year-olds believing that tariffs could improve their financial standing, though 60 percent still believe the contrary. Consumers in the middle of the earning spectrum—those making between $75,000 and $99,999, to be exact—were the most likely to disdain the administration's tariff strategy for its effects on their finances, at 70 percent. Americans who make less than $50,000 per year were closely aligned at 65 percent, and so were those making $100,000 or more at 68 percent. Economists largely believe that tariffs stand only to help—or at least, not harm—high-income earners. Data shows that duties will disproportionately burden those earning less, as they're likely to feel the pinch sooner. The Yale Budget Lab estimates that tariffs could raise average prices on goods by 1.5 percent, adding an effective annual tax of nearly $2,500 per American household. Sign in to access your portfolio
